Patents by Inventor Mathew D. Minardi

Mathew D. Minardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combretastatin A-3 prodrug
    Patent number: 7547686
    Abstract: A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (lOa-lOl) containing selected anions was achieved. Both the diphosphate sodium (lOa) and potassium salts (lOc) displayed aqueous solubility in excess of 220 mg/ml at room temperature and good cancer cell line inhibitory activity.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 16, 2009
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University
    Inventors: George R. Pettit, Mathew D. Minardi
  • Halocombstatins and methods of synthesis thereof
    Patent number: 7507851
    Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: March 24, 2009
    Assignee: Arizona Board of Regents, a state corporate of the State of Arizona, acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Mathew D. Minardi, Heidi J. Rosenberg
  • Halocombstatins and methods of synthesis thereof
    Patent number: 7223747
    Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: May 29, 2007
    Assignee: Arizona Board of Regents Acting for and on Behalf of Arizona State University
    Inventors: George R. Pettit, Mathew D. Minardi, Heidi J. Rosenberg
  • Combretastatin a-3 prodrug
    Publication number: 20040029838
    Abstract: A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting front methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (IOa-IOl) containing selected anions was achieved.
    Type: Application
    Filed: April 7, 2003
    Publication date: February 12, 2004
    Inventors: George R. Pettit, Mathew D Minardi